NORTH LIBERTY, Iowa, May 22, 2012 (GLOBE NEWSWIRE) -- KemPharm, Inc. (“KemPharm”), a clinical-stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, today provided an update on its business and development stage programs. The Company plans to leverage its deep pipeline of new chemical entities (NCEs) designed to improve the safety of opioid-based pain therapies by reducing the potential for drug abuse and diversion as well as reducing or eliminating the side effect of opioid-induced constipation (OIC). KemPharm is currently seeking a development and commercialization partner for its lead product, KP201, which is on track to file for FDA-approval in mid-2013.
